Safety Assessment of Cyclin-Dependent Kinase 4/6 Inhibitors and Comparison of Time to Adverse Events
November 2025
in “
PLoS ONE
”
Studysummary This study found that CDK4/6 inhibitors for HR+/HER2- advanced breast cancer are linked to typical adverse events such as fatigue and neutropenia, while also identifying unexpected reactions, highlighting potential safety concerns in their real-world use.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
Read the full study on journals.plos.org →